title: KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.
abstract: The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the RAS-RAF-MEK-ERK (MAPK) pathway have resulted in enhanced understanding of the KRAS mutant NSCLC and have provided optimism that this disease can be targeted.
authors.affiliation: University of Pittsburgh Cancer Institute, 5150 Centre Avenue, Room 461, Pittsburgh, PA, 15232, USA. bhattacharyas3@upmc.edu.
authors.forename: Saveri
authors.initials: S
authors.lastname: Bhattacharya
authors.affiliation: Medicine and Cardiothoracic Surgery, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, Room 556, Pittsburgh, PA, 15232, USA. socinskima@upmc.edu.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Socinski
authors.affiliation: University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Office: Suite 2.18e, Pittsburgh, PA, 15232, USA. burnstf@upmc.edu.
authors.forename: Timothy F
authors.initials: TF
authors.lastname: Burns
keywords: KRAS mutant NSCLC; MAPK pathway; Targeted therapy